pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

780 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT785Endpoints590BioPharma Dive228onclive165BioSpace63Fierce Biotech63raps25
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology6Hematology
  • A different approach to lowering healthcare costs
    Last month, Garner Health raised $100 million, vaulting its valuation to $2.7 billion. At first, this startup sounded more like a doctor-rankings company, which I’d typically think of as more ...
    Endpoints · 1mo ago↗ source
  • How K Health moved AI chatbots into hospitals
    Startups that fashion themselves as AI doctors that patients can chat with have gained traction over the last year. One of these startups, K Health, began in 2016 as a symptom checker ...
    Endpoints · 1mo ago↗ source
  • Lilly offers up to $1B for Alzheimer's drug; Bial cuts failed Parkinson's drug
    Plus news about Parabilis Medicines, RA Capital, Tango Therapeutics, Ideaya Biosciences, Bavarian Nordic and Cartesian Therapeutics 💸 Lilly’s $1B Alzheimer’s deal: The Indianapolis drugmaker wil…
← prev
page 13 of 32
next →
6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
Endpoints · 1mo ago
↗ source
  • Trodelvy misses in lung cancer, but Gilead and Merck have an HIV success
    Gilead Sciences and Merck have reported a hit and a miss for their Phase 3 HIV and lung cancer programs, respectively, but investors were largely braced for impact, according to Wall Street. The…
    Endpoints · 1mo ago↗ source
  • Endpoints Women in Biopharma: Nominate for 2026
    Today we’re opening nominations for our eighth annual Women in Biopharma special project. Women in Biopharma is one of my favorite traditions at Endpoints. Each year, we take a hard look at the s…
    Endpoints · 1mo ago↗ source
  • Pharma and biotech salaries: Top-paying companies of 2025
    The typical worker in biopharma made $116,648 in 2025, according to an Endpoints News pay analysis, earning about 30% more than the typical employee of an S&P 500 company. The latest Endpoint…
    Endpoints · 1mo ago↗ source
  • Post-Hoc Live: How much is everyone in biopharma getting paid?
    The one law of CEO pay packages: They keep getting bigger. Yesterday, we published the first installment of Endpoints News’ annual biopharma compensation project. Following our analysis of the in…
    Endpoints · 1mo ago↗ source
  • WuXi AppTec added to Pentagon's list of companies linked to Chinese military
    Another wave of scrutiny has hit WuXi AppTec through its re-inclusion in the Pentagon’s updated list of companies that have ties to the Chinese military. With its appearance on the list ...
    Endpoints · 1mo ago↗ source
  • GSK to acquire Nuvalent and its two cancer drugs under FDA review for $10.6B
    GSK is making one of the largest biotech acquisitions in its history to gain access to two experimental lung cancer medicines that are due for FDA approval decisions later this year. The UK drugm…
    Endpoints · 1mo ago↗ source
  • #ADA26: AstraZeneca's GLP-1 pill cuts weight by 10.5% after six months
    The race to be third to market with an obesity pill has a number of contenders, including Roche, Pfizer and Structure Therapeutics. On Monday, AstraZeneca set out its own stall with data on a pill ...
    Endpoints · 1mo ago↗ source
  • Incyte CEO sees $2B Vega deal aiding a post-Jakafi future
    Bill Meury has been in or led the C-suite of several biopharma companies that have constructed multibillion-dollar exits over the past decade: Allergan, Karuna and Anthos. Now, he’s the one buyin…
    Endpoints · 1mo ago↗ source
  • City Therapeutics gets $99M to gather data on three RNAi medicines
    City Therapeutics, the next-gen RNAi startup founded and led by former Alnylam executives, has collected $99.5 million to fund the clinical development of its first three candidates and expand into…
    Endpoints · 1mo ago↗ source
  • GoHealth files for bankruptcy, as Medicare Advantage insurers pull back
    The volatile Medicare Advantage market can now count GoHealth as a casualty. GoHealth, a health insurance marketplace focused on seniors, on Sunday voluntarily filed for Chapter 11 bankruptcy in…
    Endpoints · 1mo ago↗ source
  • Treeline to go public via reverse merger with Standard BioTools
    Treeline Biosciences has shared plans to debut on public markets through a reverse merger with Standard BioTools in a move that should give the company a cash runway through 2029. The
    Endpoints · 1mo ago↗ source
  • J&J makes $1B move for Firefly Bio, Carolyn Bertozzi's twist on ADCs in KRAS field
    Johnson & Johnson is making another early-stage oncology deal, dishing out $1 billion in cash to acquire Firefly Bio, a preclinical startup working on degrader antibody conjugates. J&J no…
    Endpoints · 1mo ago↗ source
  • GSK inks multi-target pact with Engitix; Sangamo considers strategic options
    Plus news about Pfizer's latest label expansion. 🤝 GSK inks multi-target liver pact with Engitix: London-based Engitix will use disease models based on its extracellular matrix technology to ide…
    Endpoints · 1mo ago↗ source
  • Tango plans Phase 3 pancreatic cancer study after combo success
    Will 2026 be remembered as the year when pancreatic cancer finally became treatable? Following Revolution Medicines’ smashing success at the annual American Society of Clinical Oncology meeting l…
    Endpoints · 1mo ago↗ source
  • Coming Soon
    Next installments of the biopharma pay series coming soon
    Endpoints · 1mo ago↗ source
  • Biopharma's top-paid CEOs of 2025: 25 making $25M+
    For the first time in four years, Endpoints News is raising the bar for what it means to be a top-paid CEO. The previous floor of $20 million is no longer rich enough. The biopharma ...
    Endpoints · 1mo ago↗ source
  • Cavalry Biosciences pursues $75M Series B to test eye and muscle disorder drugs
    Cavalry Biosciences, the first biotech out of incubator and investor Jupiter Bioventures, is working on a $75 million Series B to bring its first two drug candidates into clinical testing, CEO Pres…
    Endpoints · 1mo ago↗ source
  • #ADA26: Novo Nordisk targets 2030 launch for triple-G obesity shot
    The molecules known as triple-Gs — agonists of GLP-1, GIP and glucagon — are drawing attention as data build suggesting they could be the most effective class of obesity drugs. Eli Lilly is leading…
    Endpoints · 1mo ago↗ source
  • Incyte to buy bleeding disorder biotech Vega Therapeutics in $1.25B upfront deal
    Incyte plans to spend $1.25 billion upfront to buy Star Therapeutics' subsidiary Vega Therapeutics and its Phase 3 bleeding disorder candidate, the companies said Monday. The deal package also incl…
    Endpoints · 1mo ago↗ source
  • Takeda says it expects to take $2.5B hit after Amitiza antitrust verdict, with plans to appeal
    Takeda has updated its financial results to reflect costs it could incur after losing an antitrust lawsuit concerning its laxative drug Amitiza. In May, the US District Court in Massachusetts rul…
    Endpoints · 1mo ago↗ source
  • Nurix to work with Roche on BTK degrader in pact worth up to $2.3B
    Roche is set to pay Nurix Therapeutics $700 million upfront to collaborate on a BTK degrader for B cell malignancies, with broader plans in immunology and neurology. The deal could be ...
    Endpoints · 1mo ago↗ source
  • #ADA26: 19% of Phase 3 patients quit Boehringer obesity shot over side effects
    Boehringer Ingelheim’s obesity asset survodutide, which it licensed from Zealand Pharma, has shown high rates of discontinuations in its Phase 3 obesity study. In April, data from the SYNCHRONIZE…
    Endpoints · 1mo ago↗ source